Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2012

View Archived Issues

Novel GlyT1 inhibitors developed

Canadian study assesses involvement of neuroinflammation in healthy aging humans

Agenus and GSK expand license agreement for vaccine adjuvant

FDA clears IND application for phase III trial of melanoma vaccine

Phase III SAR-1118 trial completes enrollment

Palatin Technologies completes enrollment in phase IIb bremelanotide trial

Bayer HealthCare obtains new product approval

Isis launches phase I trial of first-generation antisense drug

Novel candidate schizophrenia therapies patented by Takeda

RaQualia Pharma presents novel sodium channel antagonists

Roche develops new inhibitors of tyrosine-protein kinase BTK

Novel phosphodiesterase 9A inhibitors reported

Celgene completes acquisition

NeuroTherapeutics Pharma divulges new GABA(A) receptor antagonists

Researchers in U.S. design new therapeutics for radiation injury

Benitec Biopharma enters into new licensing agreement

University of Dundee and GSK to target neglected parasitic diseases

Apexigen grants license for APX-004 development in China

Viral Genetics submits pre-IND for Lyme disease treatment

Gene-modified stem cell therapy shows promise to combat HIV infection

Study of AEZS-130 in cancer cachexia begins

Thrombotech clear to test THR-18 in U.S.

Apogenix's phase II trial in glioblastoma multiforme meets primary endpoint

Repligen submits MAA for SecreFlo

Recombinant protein therapy active against HIV in phase II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...